# Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

> **NCT04086485** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (estimated)

## Conditions studied

- Gastroenteropancreatico Tumors
- Neuroendocrine Tumors
- Neuroendocrine Neoplasms

## Interventions

- **DRUG:** Lu-177-DOTATATE
- **DRUG:** Olaparib
- **DIAGNOSTIC_TEST:** Ga dotatate scanning
- **DIAGNOSTIC_TEST:** FDG-PET scanning
- **DRUG:** Amino Acid infusion

## Key facts

- **NCT ID:** NCT04086485
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-03
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04086485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04086485, "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04086485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*